Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1994 Nov;39(6):391–396. doi: 10.1007/BF01534426

Unprimed CD4+ and CD8+ T cells can be rapidly activated by a CD3×CD19 bispecific antibody to proliferate and become cytotoxic

Inez-Anne Haagen 1,✉, Wim B M de Lau 1, Bert J E G Bast 1, Anette J G Geerars 1, Mike R Clark 2, Bert C de Gast 3
PMCID: PMC11038874  PMID: 7528094

Abstract

We previously reported that a CD3×CD19 bispecific antibody (bsAb) can induce efficient killing of tumour cells by preactivated T cells isolated from patients with B cell malignancy. For future intravenous application we investigated whether resting T cells from peripheral blood can be stimulated to proliferate and become cytotoxic with the CD3×CD19 bsAb alone. Indeed peripheral blood mononuclear cells, isolated from healthy donors or patients with B cell malignancy, started to proliferate within 1 day in response to CD3×CD19 bsAb. Within the same time spaancytotoxic activity against CD19-positive tumour cells was already detectable. Maintenance of cytotoxic activity was seen during 3 days of culture but optimal lysis of the target cells then required fresh CD3×CD19 bsAb in the cytotoxicity assay. Essentially the same results for proliferation and cytotoxicity were found when separated CD4-positive and CD8-positive T cells were activated by the bsAb in the presence of autologous monocytes. These results may be relevant for the in vivo application of the bsAb when used as immunotherapy in patients with B cell malignancy.

Key Words: Immunotherapy, Bispecific monoclonal antibodies, T cell activation, Cytotoxicity

Footnotes

This work was supported by grant IKMN 90-10 from the Dutch Cancer Society. M.C. was supported by a grant from the UK Medical Research Couneil

References

  • 1.Beun GDM, van de Velde CJH, Fleuren GJ. T-cell based cancer immunotherapy: direct or redirect tumor-cell recognition? Immunol Today. 1994;15:11. doi: 10.1016/0167-5699(94)90019-1. [DOI] [PubMed] [Google Scholar]
  • 2.Blank-Voorthuis CJAC, Braakman E, Ronteltap CPM, Tilly BC, Sturm E, Warnaar SO, Bolhuis RLH. Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3. J Immunol. 1993;151:2904. [PubMed] [Google Scholar]
  • 3.de Boer M, Parren P, Dove J, Ossendorp F, van de Horst G, Reeder J. Functional characterization of a novel anti-B7 monoclonal antibody. Eur J Immunol. 1992;22:3071. doi: 10.1002/eji.1830221207. [DOI] [PubMed] [Google Scholar]
  • 4.Bohlen H, Hopff T, Manzke O, Engert A, Kube D, Wickramanayake PD, Diehl V, Tesch H. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3×CD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood. 1993;82:1803. [PubMed] [Google Scholar]
  • 5.Brissinck J, Demanet C, Moser M, Leo O, Thielemans K. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J Immunol. 1991;147:4019. [PubMed] [Google Scholar]
  • 6.Clark MR, Waldmann H. T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies. J Natl Cancer Inst. 1987;79:1393. [PubMed] [Google Scholar]
  • 7.Clark M, Bindon C, Dyer M, Friend P, Hale G, Cobbold R, Calne H, Waldmann H. The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies. Eur J Immunol. 1989;19:381. doi: 10.1002/eji.1830190224. [DOI] [PubMed] [Google Scholar]
  • 8.Demanet C, Brissinck J, Mechelen MV, Loe O, Thielemans K. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype × anti-CD3) J Immunol. 1991;147:1091. [PubMed] [Google Scholar]
  • 9.Fanger MW, Guyre PM. Bispecific antibodies for targeted cellular cytotoxicity. Trends Biotechnol. 1991;9:375. doi: 10.1016/0167-7799(91)90129-6. [DOI] [PubMed] [Google Scholar]
  • 10.Fanger MW, Morganelli PM, Guyre PM. Bispecific antibodies. Crit Rev Immunol. 1992;12:101. [PubMed] [Google Scholar]
  • 11.Ferrini S, Cambiaggi A, Sforzini S, Marciano S, Canevari S, Mezanzanica D, Colnaghi MI, Grossi CE, Moretta L. Targeting of T lymphocytes against EGF-receptor+ tumor cells by bispecific monoclonal antibodies: requirement of CD3 molecules cross-linking for T-cell activation. Int J Cancer. 1993;55:931. doi: 10.1002/ijc.2910550610. [DOI] [PubMed] [Google Scholar]
  • 12.Garrido MA, Perez P, Titus JA, Valdayo MJ, Winkler DF, Barbieri SA, Wunderlich JR, Segal DM. Targeted cytotoxic cells in human peripheral blood lymphocytes. J Immunol. 1990;144:2891. [PubMed] [Google Scholar]
  • 13.de Gast GC, Platts-Mills TAE. Functional studies on lymphocytes in adult human bone marrow. J Immunol. 1979;122:285. [PubMed] [Google Scholar]
  • 14.van de Griend RJ, Bolhuis RLH. Rapid expansion of allospecific cytotoxic T cell clones using nonspecific feeder cell lines without further addition of exogenous IL-2. Transplantation. 1984;38:401. doi: 10.1097/00007890-198410000-00017. [DOI] [PubMed] [Google Scholar]
  • 15.van de Griend RJ, Giphart MJ, van Krimpen BA, Bolhuis RLH. Human T cell clones exerting multiple cytolytic activities show heterogeneity in susceptibility to inhibition by monoclonal antibodies. J Immunol. 1984;133:1222. [PubMed] [Google Scholar]
  • 16.Haagen IA, van de Griend R, Clark M, Geerars A, Bast B, de Gast B. Killing of human leukaemia/lymphoma B cells by activated cytotoxic T lymphocytes in the presence of a bispecific monoclonal antibody (αCD3/αCD19) Clin Exp Immunol. 1992;90:368. doi: 10.1111/j.1365-2249.1992.tb05853.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hamann A. Mechanisms by lymphocyte traffic and cell targeting. Int J Cancer. 1992;7:19. [PubMed] [Google Scholar]
  • 18.Hayden MS, Linsley PS, Gayle MA, Bajorath J, Brady WA, Norris NA, Fell HP, Ledbetter JA, Gilliland LK. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumor activity from a COS cell transient expression system. Ther Immunol. 1994;1:3. [PubMed] [Google Scholar]
  • 19.Kaneoka H, Perez-Rojas G, Sasasuki T, Benike CJ, Engleman EG. Human T lymphocyte proliferation induced by a pan-T monoclonal antibody (anti-leu 4): heterogencity of response is a function of monocytes. J Immunol. 1983;131:158. [PubMed] [Google Scholar]
  • 19a.Knapp W, Dorken B, Gilks WR, Rieber EP, Schmidt RE, Stein A, von dem Borne AEGKr. Leucocyte typing IV. White cell differentiation antigens. Oxford: Oxford University Press; 1989. [Google Scholar]
  • 20.Lamers CHJ, van de Griend RJ, Braakman E, Ronteltap CPM, Benard J, Stoter G, Gratama JW, Bolhuis RLH. Optimization of culture conditions for activation and large-scale expansion of human T lymphocytes for bispecific antibody-directed cellular immunotherapy. Int J Cancer. 1992;51:973. doi: 10.1002/ijc.2910510623. [DOI] [PubMed] [Google Scholar]
  • 21.van Lier RAW, Boot JHA, Verhoeven AJ, de Groot ER, Brouwer M, Aarden LA. Functional studies with anti-CD3 heavy chain isotype switch-variant monoclonal antibodies: accessory cell-independent induction of interleukin 2 responsiveness in T cell by ε-anti-CD3. J Immunol. 1987;139:2873. [PubMed] [Google Scholar]
  • 22.de Lau WBM, Boom SE, Heije K, Griffioen AW, Braakman E, Bolhuis RLH, Tax WJM, Clevers H, Bast BJEG. Heterodimeric complex formation with CD8 and TCR by bispecific antibody sustains paracrine II-2-dependent growth of CD3+ CD8+ T cells. J Immunol. 1992;149:1840. [PubMed] [Google Scholar]
  • 23.Lotze MT, Line BR, Mathisen DJ, Rosenberg SA. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol. 1980;125:1487. [PubMed] [Google Scholar]
  • 24.Maccalli C, Mortarini R, Parmiani G, Anichini A. Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. Int J Cancer. 1994;57:56. doi: 10.1002/ijc.2910570111. [DOI] [PubMed] [Google Scholar]
  • 24a.McMichael AJ, Beverly PCL, Cobbold S, Crumpton MJ, Gilks W, Gotch FM, Hogg N, Horton M, Ling N, MacLennan ICM, Mason DY, Milstein C, Spiegelhalter D, Waldmann H. Leukocyte typing III. White cell differentiation antigens. Oxford: Oxford University Press; 1987. [Google Scholar]
  • 25.Nelson H. Targeted cellular immunotherapy with bifunctional antibodies. Cancer Cells. 1991;3:163. [PubMed] [Google Scholar]
  • 26.Saxon A, Feldhaus J, Robins A. Single step separation of human T and B cells using AET treated SRBC rosettes. J Immunol Methods. 1976;12:285. doi: 10.1016/0022-1759(76)90050-8. [DOI] [PubMed] [Google Scholar]
  • 27.Segal DM, Qian JH, Mezzanzanica D, Garrido MA, Titus JA, George AJT, Jost CR, Perez P, Wunderlich JR. Targeting of anti-tumor responses with bispecific antibodies. Immunobiology. 1992;185:390. doi: 10.1016/S0171-2985(11)80655-8. [DOI] [PubMed] [Google Scholar]
  • 28.Shen GL, Li JL, Vitetta ES. Bispecific anti-CD22/anti-CD3-ricin A chain immunotoxin is cytotoxic to Daudi lymphoma cells but not T cells in vitro and shows both A-chain-mediated and LAK-T-mediated killing. J Immunol. 1994;152:2368. [PubMed] [Google Scholar]
  • 29.Smith MJ, Norihisa Y, Ortaldo JR. Multiple cytolytic mechanisms displayed by activated human peripheral blood T cell subsets. J Immunol. 1992;148:55. [PubMed] [Google Scholar]
  • 30.Uberti JP, Joshi I, Ueda M, Martilotti F, Sensenbrenner LL, Lum LG. Preclinical studies using immobilized OKT3 to activate human T cells for adoptive immunotherapy: optimal conditions for the proliferation and induction of non-MHC-restricted cytotoxicity. Cancer Immunol Immunopathol. 1994;70:234. doi: 10.1006/clin.1994.1034. [DOI] [PubMed] [Google Scholar]
  • 31.Weiner GJ, Hillstrom JR. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol. 1991;147:4035. [PubMed] [Google Scholar]
  • 32.Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol. 1994;152:2385. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES